Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
Clinical trial NCT03409276 · COMPLETED
Trial details
- NCT number
- NCT03409276
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-16
- Primary completion
- 2020-05-11
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.